Plain-English translation of NCT06585410 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called to treat early-stage cutaneous squamous cell carcinoma (CSCC), a common type of skin cancer. works by helping your immune system recognize and attack cancer cells. The study will compare whether injecting this medication directly into the cancer lesion works as well as traditional surgical removal.
Currently, surgery is the standard treatment for early-stage CSCC, but surgery leaves a scar and carries surgical risks. Researchers want to see if this immune-boosting medication could be an effective alternative that might avoid the need for surgery altogether.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to receive either intralesional injections of the medication directly into your cancer lesion or surgical removal of the lesion. You will have regular follow-up visits to monitor how well the treatment works, check for any side effects, and assess whether the cancer has been eliminated. The study will track your progress over time to compare how effective each approach is.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
United States